Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice

BACKGROUND: Currently, metastatic hormone-sensitive prostate cancer (mHSPC) patients are often treated with docetaxel chemotherapy at the initiation of hormonal therapy. This treatment is based on the results of two pivotal trials. However, trial populations are not a representative of real-world pa...

Descripción completa

Detalles Bibliográficos
Autores principales: de Groot, Ietsen, Brinkman, Ithamar, Luijendijk-de Bruin, Daphne, Poort, Sharon, van Rooijen, Johan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546919/
https://www.ncbi.nlm.nih.gov/pubmed/34723217
http://dx.doi.org/10.1016/j.euros.2021.08.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546919/
https://www.ncbi.nlm.nih.gov/pubmed/34723217
http://dx.doi.org/10.1016/j.euros.2021.08.008

Ejemplares similares